Credit Suisse AG Increases Position in Becton, Dickinson and Company (BDX)

Credit Suisse AG boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.2% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 476,040 shares of the medical instruments supplier’s stock after buying an additional 847 shares during the period. Credit Suisse AG owned approximately 0.22% of Becton, Dickinson and worth $87,325,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Rockland Trust Co. bought a new stake in shares of Becton, Dickinson and during the first quarter worth $307,000. Wells Fargo & Company MN boosted its stake in shares of Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after buying an additional 39,362 shares during the last quarter. AMG National Trust Bank boosted its stake in shares of Becton, Dickinson and by 4.2% in the first quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock worth $1,813,000 after buying an additional 401 shares during the last quarter. Boston Financial Mangement LLC boosted its stake in shares of Becton, Dickinson and by 10.2% in the first quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock worth $10,218,000 after buying an additional 5,152 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in shares of Becton, Dickinson and by 64.2% in the first quarter. Nationwide Fund Advisors now owns 96,582 shares of the medical instruments supplier’s stock worth $17,717,000 after buying an additional 37,752 shares during the last quarter. Hedge funds and other institutional investors own 75.57% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE BDX) traded down 0.99% during midday trading on Friday, hitting $197.33. The stock had a trading volume of 256,973 shares. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The stock has a market cap of $44.91 billion, a PE ratio of 57.15 and a beta of 1.05. The stock has a 50-day moving average of $199.60 and a 200 day moving average of $188.53.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the previous year, the business earned $2.35 EPS. The business’s quarterly revenue was down 5.1% compared to the same quarter last year. Analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a yield of 1.47%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

TRADEMARK VIOLATION WARNING: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/08/18/credit-suisse-ag-increases-position-in-becton-dickinson-and-company-bdx.html.

BDX has been the topic of a number of research reports. Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Evercore ISI raised Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $186.00 to $200.00 in a report on Monday, April 24th. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Bank of America Corporation reissued a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Finally, BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $195.79.

In other Becton, Dickinson and news, EVP Ribo Alberto Mas sold 7,463 shares of Becton, Dickinson and stock in a transaction on Monday, August 14th. The shares were sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the completion of the sale, the executive vice president now owns 29,323 shares of the company’s stock, valued at approximately $5,905,945.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Nabil Shabshab sold 6,149 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $201.76, for a total transaction of $1,240,622.24. Following the sale, the insider now directly owns 15,648 shares of the company’s stock, valued at approximately $3,157,140.48. The disclosure for this sale can be found here. Insiders have sold a total of 57,631 shares of company stock valued at $11,112,178 in the last ninety days. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply